The present invention relates to new fusion proteins which consist of atumor-associated targeting element preferentially a monoclonal antibody or a fragment thereof recognizing a molecule which is preferentially expressed on human tumor cells such as the human epidermal growth factor receptor (EGFR), and a biologically active ligand such as a growth and/or differentiation factor. The resulting fusion protein may be used to deliver the biologically active ligand to a specific target cell or tissue. The new immunoconjugates can be used in tumor therapy.
申请公布号
CA2138928(A1)
申请公布日期
1995.06.25
申请号
CA19942138928
申请日期
1994.12.22
申请人
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
发明人
VON HOEGEN, ILKA;HOFMANN, UWE;JAGGLE, CARLOTA-SILVIA;STRITTMATTER, WOLFGANG;STADLMUELLER, JOERG;MATZKU, SIEGFRIED